ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 193

Tocilizumab in Adult Still’s Disease : The Israeli Experience

Ori Elkayam1, Nizar Jiries2, Zvi Dranitzki3, Shaye Kivity4, Merav Lidar5, Ofer Levy6, Mahmoud Abu-Shakra7, Hagit Sarvagil-Maman8, Hagit Padova8, Dan Caspi9 and Itzhak Rosner10, 1Rheumatology, Tel-Aviv Medical Center, Sackler Faculty of Medicine, Tel-Aviv University, Tel- Aviv, Israel, 2Rheumatology, Bnai Zion Medical Center, Israel, 3Medicine, Hadassah hebrew university, Jerusalem, Israel, 4Zabludowicz Center for Autoimmune Diseases, Sheba Medical Center, affliated to Sackler Faculty of Medicine, Tel-Aviv University Israel, Tel-Aviv, Israel, 5Medicine F, Sheba Medical Center, Ramat Gan, Israel, 6Rheumatology, Asaf Harofe Medical Center, 7Medicine and Rheumatology, Soroka Medical Centre and Ben Gurion University, Beer-Sheva, Israel, 8Rheumatology, Tel Aviv Sourasky Medical Center and the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel, 9Rheumatology, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, 10Rheumatology, Bnai Zion Medical Center / Technion Faculty of Medicine, Haifa, Israel

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Adult-onset Still's disease and tocilizumab

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases: Periodic Fever Syndromes

Session Type: Abstract Submissions (ACR)

Background/Purpose:

The objective of this study was to review the clinical and laboratory characteristics of patients with adult’s Still disease treated with tocilizumab  (TCZ) in Israel.

Methods:

 Israeli rheumatologists who have ever treated a patient suffering from adult Still’s disease with TCZ were asked to review their files with special emphasis on the symptoms of the disease (arthralgias/arthritis, fever, sore throat, pleura-pericarditis, hepatitis), number of tender and swollen joints, ESR, CRP and dosage of prednisone at the initiation of TCZ, after 6 months and at the end of follow-up.

Results: : 11 cases were ascertained. All the patients fullfilled the Yamagushi classification criteria for adult Still’s disease: 7 men, aged 33±12, mean duration of disease of 7 years ( range 1-25 years). Until treatment with TCZ, the mean number of disease modifying drugs, including TNFα blockers was 4; 7 out  of 11 have previously failed TNFα blockers. TCZ was administered at a dosage of 8 mg/kg every 4 weeks in 8 patients and every 2 weeks in 3 patients. The mean follow- up was 15 months. All the patients, except 2, completed at least 6 months of treatment . At the start of TCZ treatment, despite a mean prednisone of 31mg±28 mg/d, all the patients reported joint pain; the mean tender and swollen joints count was 12 and 8, respectively. In addition, fever was reported in 7 patients, rash in 5, pleuritis in 3 and hepatitis in 2.The mean ESR and CRP were 65 and 13, respectively. After 6 months of treatment and at the end of follow-up, the number of swollen and tender joints , the ESR and CRP and  the dosage of prednisone decreased significantly (Table 1). At the end of follow up, only 2 patients still complained of mild arthralgias and none reported systemic symptoms.

Conclusion:

TCZ is extremely efficacious in adult Still’s disease. Although randomized controlled studies are needed to confirm this observation, TCZ should be strongly considered in the treatment of patient with adult Still’s disease

 

 

Start of TCZ

After 6 months

End of follow-up

Swollen joints count

8±6

1.25±1.7*

0.7±1.2*

Tender joints count

11.9±7.7

2.25±2*

1.2±0,7*

ESR

65±32

3.4±1.5*

4.3±2.26*

CRP (mg/dl)

13±17

0.47±0.17*

0.46±0.6*

Prednisone dosage (mg/d)

31±28

4.8±3.5*

3.5±5*

  • Mean±SD; p<0.05

Mean; SD


Disclosure:

O. Elkayam,
None;

N. Jiries,
None;

Z. Dranitzki,
None;

S. Kivity,
None;

M. Lidar,
None;

O. Levy,
None;

M. Abu-Shakra,
None;

H. Sarvagil-Maman,
None;

H. Padova,
None;

D. Caspi,
None;

I. Rosner,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/tocilizumab-in-adult-stills-disease-the-israeli-experience/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology